Persistence of Anti-S Titre among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19.
Luca CoppetaGiuseppina SommaCristiana FerrariAndrea MazzaStefano RizzaMarco Trabucco AurilioStefano PerroneAndrea MagriniAntonio PietroiustiPublished in: Vaccines (2021)
The COVID-19 pandemic has led to health, social and economic consequences for public health systems. As a result, the development of safe and effective vaccines, in order to contain the infection quickly became a priority. The first vaccine approved by the Italian Agency for Drugs Authorization (AIFA) was the BNT162b2 mRNA vaccine, developed by BioNTech and Pfizer (Comirnaty). Comirnaty contains a molecule called messenger RNA (mRNA), which is a nucleoside-modified RNA that encodes the SARS-CoV-2 spike glycoprotein. Even if data from phase I suggest that vaccine induced antibodies can persist for up to six months following the second shot of BNT vaccine, data regarding the real duration of immunological protection are lacking. In this study, we aimed to evaluate the duration of serological protection by detecting the presence of anti-S-RBD (receptor-binding domain) antibodies for SARS-CoV-2 among a large group of healthcare workers (HCWs) three months after vaccination. 99% of HCWs had a detectable titre of anti-S SARS-CoV-2 antibodies 90 days after the second vaccine shot. Elderly operators showed significantly lower levels of protective antibodies when compared to the younger ones, thus they could become unprotected earlier than other operators.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- healthcare
- binding protein
- mental health
- coronavirus disease
- public health
- big data
- emergency department
- electronic health record
- machine learning
- endothelial cells
- dna binding
- risk assessment
- transcription factor
- high glucose
- artificial intelligence
- diabetic rats
- stress induced